Clinical trials: NMDAR Autoimmune Encephalitis
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis.
- Trial name
- NCT06510283
- Testing
- Taitacept
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tongren Hospital
NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis
Medium-term Effects of Treatments in Autoimmune Encephalitis
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence.
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis, CASPR2-Antibody, IgLON5
- Trial name
- META (NCT07133113)
- Testing
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 following IVIG administration in healthy participants to investigate the potential interactions between ART5803 and IVIG
- Conditions
- Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder), Autoimmune Encephalitis
- Trial name
- NCT06753955
- Testing
- ART5803, Intravenous immunoglobulin (IVIG)
- Where
- Australia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Arialys Therapeutics
Anti-NMDA Receptor Encephalitis, Mature Teratoma
A Case Report of NMDAR Encephalopathy
This case illustrates the clinical, radiologic, and histopathologic features of Anti-NMDAR encephalitis and underscores the importance of MRI in detecting ovarian teratomas when pelvic ultrasound is inconclusive.
- Conditions
- Anti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes
- Trial name
- NCT06915103
- Testing
- Magnetic Resonance Imaging (MRI), Salpingo-oophorectomy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Encephalitis, Encephalitis, Viral
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)
Based on the records of traditional Chinese medicine, CBS has the functions of purifying the heart, eliminating phlegm, stimulating bile secretion, and soothing the nerves.
- Conditions
- Encephalitis, Encephalitis, Viral, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis
- Trial name
- NCT06584045
- Testing
- Calculus bovis sativus (CBS)
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area
Anti N-methyl-D-aspartate receptor encephalitis is an autoimmune encephalitis，found in recent years，producing the specific IgG antibody induced by the NMDA receptors.It is the most common curable disease among the non…
- Trial name
- MuPRaNE (NCT02443350)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jia Wei Wang,MD
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
- Trial name
- Cielo (NCT05503264)
- Testing
- Satralizumab
- Where
- 56 sites in United States, Argentina and 13 more
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Anti-NMDAR Encephalitis
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
- Trial name
- IANMDAR (NCT03274375)
- Testing
- IA session, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris